Puma Biotechnology (PBYI) Free Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Puma Biotechnology (PBYI) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 21.16% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 45.09% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 80.69% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -4.45% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 8.92% |
| 10 | Puma Biotechnology | 486.99 Mn | 393.08 Mn | 44.03 Mn | -21.02% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -21.02% |
| Mar 31, 2026 | 80.01% |
| Dec 31, 2025 | -0.56% |
| Sep 30, 2025 | -1.92% |
| Jun 30, 2025 | 44.44% |
| Mar 31, 2025 | 28.71% |
| Dec 31, 2024 | 69.49% |
| Sep 30, 2024 | 1.62% |
| Jun 30, 2024 | 149.91% |
| Mar 31, 2024 | -10.45% |
| Dec 31, 2023 | 56.59% |
| Sep 30, 2023 | 83.66% |
| Jun 30, 2023 | -41.22% |
| Mar 31, 2023 | 30.62% |
| Dec 31, 2022 | 110.87% |
| Sep 30, 2022 | 50.43% |
| Jun 30, 2022 | -32.26% |
| Mar 31, 2022 | -18.58% |
| Dec 31, 2021 | -39.79% |
| Sep 30, 2021 | 50.18% |